Title |
A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I
|
---|---|
Published in |
Supportive Care in Cancer, May 2017
|
DOI | 10.1007/s00520-017-3760-2 |
Pubmed ID | |
Authors |
Deirdre R. Pachman, Travis Dockter, Patricia J. Zekan, Briant Fruth, Kathryn J. Ruddy, Lauren E. Ta, Jacqueline M. Lafky, Todor Dentchev, Nguyet Anh Le-Lindqwister, William M. Sikov, Nathan Staff, Andreas S. Beutler, Charles L. Loprinzi |
Abstract |
Paclitaxel is associated with both an acute pain syndrome (P-APS) and chronic chemotherapy-induced peripheral neuropathy (CIPN). Given that extensive animal data suggest that minocycline may prevent chemotherapy-induced neurotoxicity, the purpose of this pilot study was to investigate the efficacy of minocycline for the prevention of CIPN and the P-APS. Patients with breast cancer were enrolled prior to initiating neoadjuvant or adjuvant weekly paclitaxel for 12 weeks and were randomized to receive minocycline 200 mg on day 1 followed by 100 mg twice daily or a matching placebo. Patients completed (1) an acute pain syndrome questionnaire daily during chemotherapy to measure P-APS and (2) the EORTC QLQ-CIPN20 questionnaire at baseline, prior to each dose of paclitaxel, and monthly for 6 months post treatment, to measure CIPN. Forty-seven patients were randomized. There were no remarkable differences noted between the minocycline and placebo groups for the overall sensory neuropathy score of the EORTC QLQ-CIPN20 or its individual components, which evaluate tingling, numbness and shooting/burning pain in hands and feet. However, patients taking minocycline had a significant reduction in the daily average pain score attributed to P-APS (p = 0.02). Not only were no increased toxicities reported with minocycline, but there was a significant reduction in fatigue (p = 0.02). Results of this pilot study do not support the use of minocycline to prevent CIPN, but suggest that it may reduce P-APS and decrease fatigue; further study of the impact of this agent on those endpoints may be warranted. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 82 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 13 | 16% |
Student > Ph. D. Student | 10 | 12% |
Researcher | 9 | 11% |
Student > Doctoral Student | 6 | 7% |
Student > Bachelor | 6 | 7% |
Other | 11 | 13% |
Unknown | 27 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 20 | 24% |
Nursing and Health Professions | 9 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 7% |
Neuroscience | 3 | 4% |
Psychology | 2 | 2% |
Other | 5 | 6% |
Unknown | 37 | 45% |